KING PHARMACEUTICALS INC Form 424B7 July 14, 2006

Table of Contents

PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated June 23, 2006)

Filed Pursuant to Rule 424(b)(3) and 424(b)(7) File No. 333-135285

\$400,000,000

1¹/4% Convertible Senior Notes due 2026 and Shares of Common Stock Issuable Upon Conversion of the Notes and Related Subsidiary Guarantees

This prospectus supplement supersedes and replaces the section entitled Selling Securityholders contained in the prospectus, dated June 23, 2006, relating to the potential sale from time to time by the selling securityholders identified in this prospectus supplement of up to \$400,000,000 aggregate principal amount of our 1¹/4% Convertible Senior Notes due 2026, or Notes, the related guarantees issued by our domestic subsidiaries and our shares of common stock issuable upon conversion of the Notes. The terms of the Notes are set forth in the prospectus dated June 23, 2006. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus dated June 23, 2006, including any amendments or further supplements thereto, except to the extent that the information in this prospectus supplement supersedes the information contained in the prospectus dated June 23, 2006.

Investing in the Notes and our common stock issuable upon conversion of the Notes involves risks that are described in the Risk Factors section of the accompanying prospectus beginning on page 7.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT OR THE PROSPECTUS, DATED JUNE 23, 2006. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus supplement is July 14, 2006.

TABLE OF CONTENTS

	Page
Prospectus Supplement	
SELLING SECURITYHOLDERS	S-1

Table of Contents

SELLING SECURITYHOLDERS

The Notes and subsidiary guarantees were issued and sold by us in March 2006 to Citigroup Global Markets Inc., UBS Securities LLC and Banc of America Securities LLC (the initial purchasers), and were re-sold by the initial purchasers pursuant to Rule 144A under the Securities Act. The selling securityholders may from time to time offer and sell pursuant to this prospectus or a supplement hereto any or all of the Notes and subsidiary guarantees listed below and the shares of common stock issued upon conversion of such Notes. When we refer to the selling securityholders in this prospectus or a supplement hereto, we mean those persons listed in the table below, as well as the pledgees, donees, assignees, transferees, successors and others who later hold any of the selling securityholders interests.

The table below sets forth information with respect to the selling securityholders, the principal amount of Notes and related subsidiary guarantees beneficially owned by each selling securityholder that may be offered pursuant to this prospectus or a supplement hereto and the number of shares of common stock into which such Notes are initially convertible. However, the number of shares of common stock into which such Notes are initially convertible is subject to adjustment as provided in Description of the Notes Conversion Rights Conversion Rate Adjustments; resulting from payment of any make whole amount as provided in Description of the Notes Determination of the Make Whole Amount; and resulting from any registration default as provided in Description of the Notes Registration Rights. Unless set forth below, to our knowledge, none of the selling securityholders has, or within the past three years has had, any material relationship with us or any of our predecessors or affiliates or beneficially owns in excess of 1% of the outstanding common stock.

The principal amounts of the Notes provided in the table below are based on information provided to us by each of the selling securityholders as of July 13, 2006. Since the date on which each selling securityholder provided this information, each selling securityholder identified below may have sold, transferred or otherwise disposed of all or a portion of its Notes and subsidiary guarantees in a transaction exempt from the registration requirements of the Securities Act. Information concerning the selling securityholders may change from time to time and any changed information will be set forth in supplements or amendments to this prospectus to the extent required.

	Principal Amount of Notes and Subsidiary		Number of S	Shares of Com	mon Stock
	Guarantees Beneficially Owned and Offered	Notes and Subsidiary Guarantees	Beneficially	Offered	Beneficially Owned After the
Full Legal Name of Selling Securityholder(1)		Outstanding	Owned(3)	Hereby(2)(3)	Offering(2)
Allstate Insurance Company(4) Aristeia International Limited Aristeia Partners LP Black Diamond Convertible Offshore LOC	\$ 2,000,000 22,240,000 2,760,000 2,000,000	5.6%	183,539 1,067,588 132,488 96,006	96,006 1,067,588 132,488 96,006	87,533 0 0 0

Edgar Filing: KING PHARMACEUTICALS INC - Form 424B7

Black Diamond Offshore, Ltd.	1,127,000	*	54,099	54,099	0
Calamos Convertible Fund Calamos Investment					
Trust	4,650,000	1.2%	223,214	223,214	0
Citidel Equity Fund Ltd.	86,500,000	21.6%	4,152,268	4,152,268	0
Citigroup Global Markets Inc.	6,350,000	1.6%	304,819	304,819	0
CNH CA Master Account, L.P.	10,000,000	2.5%	480,031	480,031	0
CQS Convertible and Quantitative Strategies					
Master Fund Limited	40,000,000	10.0%	1,920,124	1,920,124	0
DBAG London	15,193,000	3.8%	729,311	729,311	0
Deutsche Bank Securities Inc.	1,000,000	*	48,003	48,003	0
Double Black Diamond Offshore LOC	6,873,000	1.7%	329,925	329,925	0
Fore Convertible Master Fund, Ltd.	18,254,000	4.6%	876,248	876,248	0
Fore Erisa Fund, Ltd.	1,746,000	*	83,813	83,813	0
Fore Multi Strategy Master Fund, Ltd.	5,092,000	1.3%	244,431	244,431	0
Highbridge International LLC	5,000,000	1.3%	240,015	240,015	0
	S-1				

Table of Contents

	Principal Amount of Notes and Subsidiary	Percentage of	Number of Shares of Common Stock			
Full Legal Name of Selling Securityholder(1)	Guarantees Beneficially Owned and Offered Hereby(2)	Notes and Subsidiary Guarantees Outstanding	Beneficially Owned(3)	Offered Hereby(2)(3)	Beneficially Owned After the Offering(2)	
MDGE: IID 1 / /G III IVIII	15 500 000	2.00	744.040	744.040	0	
KBC Financial Products (Cayman Islands) Ltd.	15,500,000		744,048	744,048	0	
KBC Financial Products USA Inc.	8,500,000		408,026	408,026	0	
Lydian Global Opportunities Master Fund Ltd.	5,000,000		240,015	240,015	0	
Lydian Oversees Partners Master Fund L.P.	20,000,000		960,062	960,062	0	
Man Mac I, Ltd.	3,212,000		154,185	154,185	0	
Pond Point Partners Master Fund, Ltd.	2,000,000	*	96,006	96,006	0	
Sandelman Partners Multi-Strategy Master Fund,						
Ltd.(5)	20,000,000		1,677,062	960,062	717,000	
Sphinx Fund	398,000		19,105	19,105	0	
Sutton Brook Capital Portfolio LP	25,000,000	6.3%	1,200,077	1,200,077	0	
Tempo Master Fund L.P.	10,000,000	2.5%	480,031	480,031	0	
TQA Master Fund	4,654,000	1.2%	223,406	223,406	0	
TQA Master Plus Fund	3,070,000	*	147,369	147,369	0	
Zurich Institutional Benchmark Master Fund	1,290,000	*	61,923	61,923	0	
All other holders of Notes and subsidiary						
guarantees or future transferees, pledgees, donees						
or successors of any such holders(6)	50,591,000	12.6%	2,428,524	2,428,524	0	
TOTAL	\$ 400,000,000	100.0%	20,005,764	19,201,231	804,533	

^{*} Less than 1%.

S-2

⁽¹⁾ Certain selling securityholders are, or are affiliates of, registered broker-dealers. These selling securityholders have represented that they acquired their securities in the ordinary course of business and, at the time of the acquisition of the securities, had no agreements or understandings, directly or indirectly, with any person to distribute the securities. To the extent that we become aware that any such selling securityholders did not acquire its securities in the ordinary course of business or did have such an agreement or understanding, we will file a post-effective amendment to the registration statement of which this prospectus is a part to designate such person as an underwriter within the meaning of the Securities Act of 1933.

Table of Contents

- (2) We do not know when or in what amounts a selling securityholder may offer the Notes, subsidiary guarantees or shares of common stock for sale. The selling securityholder might not sell any or all of the Notes and subsidiary guarantees or shares offered by this prospectus. Because the selling securityholders may offer all or some of the Notes and subsidiary guarantees or shares pursuant to this offering, we cannot estimate the number of the Notes and subsidiary guarantees or shares that will be held by the selling securityholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion of the offering, none of the Notes and subsidiary guarantees or shares covered by this prospectus will be held by the selling securityholders.
- (3) Amounts assume conversion of all the selling securityholders Notes at the initial conversion rate of 48.0031 shares of common stock per \$1,000 principal amount of Notes, excluding fractional shares. However, the conversion ratio, and therefore the number of shares of our common stock issuable upon conversion of the Notes, is subject to adjustment. Accordingly, the number of shares of common stock issuable upon conversion of the Notes may increase or decrease.
- (4) Beneficial ownership includes the following additional shares of common stock which are not being offered hereby and which we have assumed will remain outstanding after the offering: 13,333 shares currently held by Allstate Insurance Company, 15,700 shares held by Agents Pension Plan and 58,000 shares of common stock held by Allstate Retirement Plan.
- (5) Beneficial ownership includes 717,000 additional shares of common stock which are not being offered hereby and which we have assumed will remain outstanding after the offering.
- (6) Amounts assume that any other holders of Notes and subsidiary guarantees, or any future transferee, pledgee, donee or successor of any such other holders of Notes and subsidiary guarantees, do not beneficially own any shares of our common stock other than the shares of our common stock issuable upon conversion of the Notes. Such persons shall not be permitted to sell pursuant to the registration statement unless and until they are listed in the selling securityholders—table in a supplement to this prospectus supplement.

S-3